Concord Biotech Ltd vs Sakar Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Concord Biotech Ltd is ₹ 1223 as of 06 May 15:30 . The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 47.2 on March 2025 . This represents a CAGR of -4.45% over 2 yearsThe P/E Ratio of Sakar Healthcare Ltd changed from 16.5 on March 2021 to 26.6 on March 2025 . This represents a CAGR of 10.02% over 5 years The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 17537 crore on March 2025 . This represents a CAGR of 4.95% over 2 yearsThe Market Cap of Sakar Healthcare Ltd changed from ₹ 176.64 crore on March 2021 to ₹ 464.72 crore on March 2025 . This represents a CAGR of 21.34% over 5 years The revenue of Concord Biotech Ltd for the Dec '25 is ₹ 287.74 crore as compare to the Sep '25 revenue of ₹ 262.7 crore. This represent the growth of 9.53% The revenue of Sakar Healthcare Ltd for the Dec '25 is ₹ 70.85 crore as compare to the Sep '25 revenue of ₹ 58.78 crore. This represent the growth of 20.53% The ebitda of Concord Biotech Ltd for the Dec '25 is ₹ 104.98 crore as compare to the Sep '25 ebitda of ₹ 104.13 crore. This represent the growth of 0.82% The ebitda of Sakar Healthcare Ltd for the Dec '25 is ₹ 19.1 crore as compare to the Sep '25 ebitda of ₹ 12.57 crore. This represent the growth of 51.95% The net profit of Concord Biotech Ltd changed from ₹ 59.59 crore to ₹ 63.64 crore over 7 quarters. This represents a CAGR of 3.83% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 10.25 crore over 7 quarters. This represents a CAGR of 128.70% The Dividend Payout of Concord Biotech Ltd changed from 2.73 % on March 2022 to 24.54 % on March 2025 . This represents a CAGR of 73.15% over 4 yearsThe Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Concord Biotech Ltd

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

FAQs for the comparison of Concord Biotech Ltd and Sakar Healthcare Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Sakar Healthcare Ltd?

Market cap of Concord Biotech Ltd is 12,795 Cr while Market cap of Sakar Healthcare Ltd is 1,330 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Sakar Healthcare Ltd?

The stock performance of Concord Biotech Ltd and Sakar Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Sakar Healthcare Ltd?

As of May 6, 2026, the Concord Biotech Ltd stock price is INR ₹1223.05. On the other hand, Sakar Healthcare Ltd stock price is INR ₹598.0.

How do dividend payouts of Concord Biotech Ltd and Sakar Healthcare Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Sakar Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.